JWH-356

JWH-356 is a synthetic cannabinoid that acts as a selective agonist for the cannabinoid receptors. It is part of the naphthoylindole family of compounds, which are known for their high affinity and selectivity for the CB2 receptor over the CB1 receptor.

Chemical Structure and Properties

JWH-356 has the chemical formula C₂₁H₂₃NO₂ and a molecular weight of 321.41 g/mol. The compound is characterized by a methoxyphenyl group attached to the indole core, which is linked to a pentyl chain. This structure is similar to other compounds in the JWH series, which were developed by John W. Huffman and his team at Clemson University.

Pharmacology

JWH-356 is a potent agonist of the CB2 receptor, with a high selectivity over the CB1 receptor. This selectivity makes it of interest for research into the therapeutic potential of CB2 receptor agonists, which are thought to have anti-inflammatory and immunomodulatory effects without the psychoactive effects associated with CB1 receptor activation.

Receptor Binding

JWH-356 binds to the CB2 receptor with a high affinity, which is quantified by its low nanomolar binding constant. The selectivity for CB2 over CB1 is significant, making it a useful tool in research to differentiate the roles of these receptors in various physiological processes.

Potential Applications

Research into JWH-356 and similar compounds is ongoing, with potential applications in the treatment of conditions such as chronic pain, inflammation, and autoimmune diseases. The selective activation of CB2 receptors is particularly promising for developing medications that do not produce the psychoactive effects typical of cannabinoids that activate CB1 receptors.

Legal Status

The legal status of JWH-356 varies by country. In many jurisdictions, it is classified as a controlled substance due to its structural similarity to other synthetic cannabinoids that have been associated with recreational use and potential health risks.

Safety and Toxicology

As with many synthetic cannabinoids, the safety profile of JWH-356 is not well-established. Research is needed to fully understand its pharmacokinetics, potential toxicity, and long-term effects. Caution is advised in handling and studying this compound.

Also see

• Cannabinoid receptor
• Synthetic cannabinoids
• CB1 receptor
• CB2 receptor
• John W. Huffman